Takeda Pharmaceutical Co. Ltd. Purchases New Position in HilleVax, Inc. (NASDAQ:HLVX)

Takeda Pharmaceutical Co. Ltd. bought a new position in HilleVax, Inc. (NASDAQ:HLVX) during the 4th quarter, HoldingsChannel reports. The fund bought 6,724,000 shares of the company’s stock, valued at approximately $13,919,000. HilleVax accounts for about 52.4% of Takeda Pharmaceutical Co. Ltd.’s holdings, making the stock its biggest holding. Takeda Pharmaceutical Co. Ltd. owned approximately 0.13% of HilleVax at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Intech Investment Management LLC bought a new stake in HilleVax during the fourth quarter worth about $26,000. SG Americas Securities LLC grew its position in HilleVax by 61.6% during the 4th quarter. SG Americas Securities LLC now owns 18,145 shares of the company’s stock worth $38,000 after acquiring an additional 6,916 shares during the last quarter. Ieq Capital LLC increased its holdings in HilleVax by 71.1% during the 4th quarter. Ieq Capital LLC now owns 22,495 shares of the company’s stock valued at $47,000 after purchasing an additional 9,344 shares in the last quarter. Barclays PLC raised its position in HilleVax by 255.6% in the 3rd quarter. Barclays PLC now owns 42,033 shares of the company’s stock valued at $74,000 after purchasing an additional 30,213 shares during the last quarter. Finally, Jane Street Group LLC boosted its stake in HilleVax by 81.7% in the third quarter. Jane Street Group LLC now owns 79,039 shares of the company’s stock worth $139,000 after purchasing an additional 35,546 shares in the last quarter. Institutional investors and hedge funds own 86.42% of the company’s stock.

HilleVax Stock Performance

Shares of HLVX stock opened at $1.61 on Thursday. The stock’s fifty day moving average is $1.83 and its 200-day moving average is $1.86. HilleVax, Inc. has a 52 week low of $1.55 and a 52 week high of $17.23. The stock has a market capitalization of $80.19 million, a PE ratio of -0.52 and a beta of 0.76.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.